Bristol Myers Squibb (BMS) and Nektar Therapeutics announced a collaboration in which BMS’ PD-1 checkpoint inhibitor (Opdivo, nivolumab) will be combined with Nektar;s CD-122 agonist NKTR-214. Continue reading
Tag Archives: T-cells

Unum’s Antibody-Directed T Cells: Differentiated from CAR T-Cell and T Cell Receptor Reprogramming
Unum Therapeutics is a new immunotherapy biotechnology company in which Fidelity Biosciences, Atlas Ventures and Sanofi invested $12 MM in a Series A (first venture round) of investment. Continue reading